What Makes Patients Feel Safe During Ketamine Treatment?

Summary of Paper: Feeling safe: an empirical-ethical analysis of vulnerability in (es)ketamine treatment

What is it about?

Picture a patient lying on a treatment bed. A few minutes ago they received a dose of ketamine. The room now feels far away, time has stopped behaving normally, and they are not quite sure where their body ends. Next to them, a clinician is typing on a laptop.

Medically, nothing is going wrong. Blood pressure is checked and the protocol is followed. Yet one patient told us that in this situation they felt like “a product on a conveyor belt.”

This is the kind of moment our study is about. Ketamine, given as a nasal spray or an intravenous infusion, is now used to treat depression that hasn’t responded to other treatments. Unlike most antidepressants, it changes how people experience themselves and the world within minutes. For a while, it also makes it harder to speak up, ask for help or say no. We wanted to understand what makes people feel safe in that state, so we talked with 14 patients and 10 clinicians in Germany.

Why is it important?

For many patients, ketamine is one of the last options left after years of depression. If they don’t feel safe, they may never start, or they may stop partway through, even when the treatment could help.

Earlier studies already told us that trust, preparation and a good setting matter. But they rarely said what that looks like in practice. What should a clinician actually do, or avoid doing?

There is also a distinction that is easy to miss. Being safe is not the same as feeling safe. The patient next to the laptop was safe in the medical sense, but they did not feel safe. This raises an ethical question: what does a clinic owe someone whose ability to look after themselves has been reduced by the very treatment the clinic gave them?

Main findings

  • People's worries before treatment take different forms. Some patients were afraid of an LSD-like trip or of developing psychosis. Others played the experience down, calling it just “side effects.” One patient asked her doctor to tell her only the basics so she wouldn’t overthink it. Calm, in other words, did not always mean prepared.
  • Being in the room is not the same as being there. One patient described a psychiatrist who sat right beside them: “he gave me safety.” Others described the opposite: a clinician checking emails, or contact that never went beyond a blood pressure check.
  • Sometimes a hand helps. One patient asked to have their hand held during a frightening moment, and in that moment wondered “Do I exist still?” The touch reminded them that there was a body there after all.
  • The end of a session is a vulnerable moment. Patients described being “spat out” into a busy world, or “discharged by the clock.” A short talk or a cup of tea together afterwards made a real difference. We call this kind of support a “landing aid.”
  • Not everyone feels safe in the same way. Some patients wanted clear, expert-level explanations. Others found comfort in warmth and medical authority. Still others preferred to be left alone with an eye mask and music, or brought friends along.
  • Patients and clinicians often understood ketamine differently. Clinicians tended to see it as a catalyst for deeper change. Patients more often saw it as a moment of relief or simply as a medication. When these pictures don’t match, a patient’s needs can easily go unnoticed.

What do the authors argue?

Our main argument is simple. The clinic creates the patient’s vulnerable state, and the patient then depends on that same clinic, so the clinic carries a special responsibility. The goal is not to remove that vulnerability. Letting go is part of how the treatment works. The goal is to make it a state people can get through feeling cared for.

In practice, this means preparing patients for the experience itself, not just for the side effects, in as much detail as each person wants. It means staying attentive during the session, ending each session with a proper landing, and asking patients beforehand what helps them feel safe. Waiting for them to say it while they are under the drug’s effects is too late. It also means talking with patients about how they think ketamine works.

One recommendation surprised even us. Our interviews suggested that hand-holding can be helpful. Even so, we argue that touch should be agreed before treatment begins, never offered on the spot. And if a patient has said no in advance, that answer should still hold during the session, because in that moment the drug takes away the very ability to weigh the decision. In this case our ethical analysis pushed back against our own findings.

Many of these changes cost very little. Small gestures of care were often enough to make patients feel seen. This was a small, exploratory study in Germany, so the findings still need to be tested in larger and more varied groups.

Team Member Spotlight

Dr. Adrian Kind is a clinical psychologist, philosopher who works as postdoctoral researcher at Charité Berlin and a Junior Fellow of the German Center for Mental Health (DZPG). He earned his doctorate in the DFG Research Training Group “Extrospection” at the Berlin School of Mind and Brain and Otto von Guericke University Magdeburg. His work brings together philosophy of mind and psychiatry. He teaches philosophy and psychotherapy, serves on the board of the German Society for Psychodynamic Therapy (DFT) and, among other activities, contributed to the recent update of Germany’s national S3 guideline on unipolar depression.

You can find the paper here.